Floatz logo

ETOPOSIDE

Esophagogastric Junction Neoplasms

AstraZenecaSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

47 Active assets in the Esophagogastric Junction Neoplasms cohort.

Asset / SponsorPhaseRating
Carboplatin
Iambic Therapeutics, Inc
Phase 1/2B
Eloxatin
Incyte Corporation
Phase 1/2B
FLUOROURACILUM
Incyte Corporation
Phase 1/2B
Cyclophosphamide
Diwakar Davar
Phase 2B
Pembrolizumab
Diwakar Davar
Phase 2B

View all 50 →

Same molecule, other indications

ETOPOSIDE is also rated in:

acute megakaryoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
acute monocytic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
acute myeloblastic leukemia with maturationDormant
BBB
Indicative ·
79 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →